Page 53 - AN-2-1

Advanced Neurology Piribedil for Parkinson’s disease

2016: A systematic analysis for the Global Burden of Disease https://doi.org/10.1016/j.pharmthera.2010.06.002
Study 2016. Lancet Neurol, 17: 939–953.
18. Burbulla LF, Song P, Mazzulli JR, et al., 2017, Dopamine
https://doi.org/10.1016/S1474-4422(18)30295-3 oxidation mediates mitochondrial and lysosomal
dysfunction in Parkinson’s disease. Science, 357: 1255–1261.
7. Moustafa AA, Chakravarthy S, Phillips JR, et al., 2016, Motor
symptoms in Parkinson’s disease: A unified framework. https://doi.org/10.1126/science.aam9080
Neurosci Biobehav Rev, 68: 727–740.
19. García-Sanz P, Orgaz L, Bueno-Gil G, et al., 2017, N370S-
https://doi.org/10.1016/j.neubiorev.2016.07.010 GBA1 mutation causes lysosomal cholesterol accumulation
in Parkinson’s disease. Mov Disord, 32: 1409–1422.
8. Church FC, 2021, Treatment options for motor and non-
motor symptoms of Parkinson’s disease. Biomolecules, https://doi.org/10.1002/mds.27119
11: 612.
20. Mosharov EV, Larsen KE, Kanter E, et al., 2009, Interplay
https://doi.org/10.3390/biom11040612 between cytosolic dopamine, calcium, and alpha-synuclein
causes selective death of substantia nigra neurons. Neuron,
9. Poewe W, 2008, Non-motor symptoms in Parkinson’s
disease. Eur J Neurol, 15: 14–20. 62: 218–229.
https://doi.org/10.1016/j.neuron.2009.01.033
https://doi.org/10.1111/j.1468-1331.2008.02056.x
21. Fouillet A, Levet C, Virgone A, et al., 2012, ER stress inhibits
10. Müller B, Assmus J, Herlofson K, et al., 2013, Importance of
motor vs. non-motor symptoms for health-related quality of neuronal death by promoting autophagy. Autophagy, 8: 915–926.
life in early Parkinson’s disease. Parkinsonism Relat Disord, https://doi.org/10.4161/auto.19716
19: 1027–1032.
22. Valdés P, Mercado G, Vidal RL, et al., 2014, Control of
https://doi.org/10.1016/j.parkreldis.2013.07.010 dopaminergic neuron survival by the unfolded protein
11. Rajiah K, Maharajan MK, Yeen SJ, et al., 2017, Quality response transcription factor XBP1. Proc Natl Acad Sci U S
of life and caregivers’ burden of Parkinson’s disease. A, 111: 6804–6809.
Neuroepidemiology, 48: 131–137. https://doi.org/10.1073/pnas.1321845111
https://doi.org/10.1159/000479031 23. Cai Y, Arikkath J, Yang L, et al., 2016, Interplay of endoplasmic
12. Pilipovich AA, Golubev VL, 2017, The agonist of dopamine reticulum stress and autophagy in neurodegenerative
receptors piribedil in treatment of Parkinson’s disease. disorders. Autophagy, 12: 225–244.
Zh Nevrol Psikhiatr Im S S Korsakova, 117: 83–90. https://doi.org/10.1080/15548627.2015.1121360
https://doi.org/10.17116/jnevro20171176183-90 24. Xilouri M, Brekk OR, Polissidis A, et al., 2016, Impairment
13. Chen S, Chen H, 2020, Chinese Parkinson’s disease and of chaperone-mediated autophagy induces dopaminergic
movement disorder society Chinese guidelines for the neurodegeneration in rats. Autophagy, 12: 2230–2247.
treatment of Parkinson’s disease (fourth edition). Chin J https://doi.org/10.1080/15548627.2016.1214777
Neurol, 53: 973–986.
25. Beaulieu JM, Gainetdinov RR, 2011, The physiology,
14. NICE Guideline [NG71]-Parkinson’s Disease in Adults. signaling, and pharmacology of dopamine receptors.
Parkinson’s UK. Available from: https://www.parkinsons. Pharmacol Rev, 63: 182–217.
org.uk/professionals/resources/nice-guideline-ng71-
parkinsons-disease-adults [Last accessed on 2021 May 22]. https://doi.org/10.1124/pr.110.002642
26. Yang P, Perlmutter JS, Benzinger TL, et al., 2020, Dopamine
15. Ferreira JJ, Katzenschlager R, Bloem BR, et al., 2013, D3 receptor: A neglected participant in Parkinson Disease
Summary of the recommendations of the EFNS/MDS-ES pathogenesis and treatment? Ageing Res Rev, 57: 100994.
review on therapeutic management of Parkinson’s disease.
Eur J Neurol, 20: 5–15. https://doi.org/10.1016/j.arr.2019.100994
https://doi.org/10.1111/j.1468-1331.2012.03866.x 27. Jenner P, 1992, Parkinson’s disease: Pathological mechanisms
and actions of piribedil. J Neurol, 239: S2–S8.
16. Thobois S, 2006, Proposed dose equivalence for rapid switch
between dopamine receptor agonists in Parkinson’s disease: https://doi.org/10.1007/BF00819559
A review of the literature. Clin Ther, 28: 1–12.
28. Millan MJ, Cussac D, Milligan G, et al., 2001,
https://doi.org/10.1016/j.clinthera.2005.12.003 Antiparkinsonian agent piribedil displays antagonist
properties at native, rat, and cloned, human alpha(2)-
17. Millan MJ, 2010, From the cell to the clinic: A comparative
review of the partial D₂/D₃receptor agonist and adrenoceptors: Cellular and functional characterization.
α2-adrenoceptor antagonist, piribedil, in the treatment of J Pharmacol Exp Ther, 297: 876–887.
Parkinson’s disease. Pharmacol Ther, 128: 229–273. 29. Perez-Lloret S, Rascol O, 2016, Piribedil for the treatment of

Volume 2 Issue 1 (2023) 11 https://doi.org/10.36922/an.290